Citius Pharmaceuticals Inc vs ProShares UltraPro S&P500 — how do they compare? Citius Pharmaceuticals Inc trades at $0.73 (market cap $20.01M), while ProShares UltraPro S&P500 trades at $155.33. The key difference: ProShares UltraPro S&P500 is trading nearer its 52-week high, Citius Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| CTXR | UPRO | |
|---|---|---|
Market Cap | $20.01M | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $1.82 | $155.10 |
52-Week Low | $0.48 | $89.29 |
Enterprise Value | $16.23M | — |
Trailing returns across standard periods
Latest headlines on both assets
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →UPRO is a leveraged ETF that seeks daily investment results, before fees and expenses, that correspond to three times (3x) the daily performance of the S&P 500 Index. It is a tactical, high-conviction instrument designed for short-term traders to amplify bullish market moves, utilizing a daily reset mechanism that creates significant compounding effects and volatility risks over time.
Read more on UPRO →